{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-055156","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.240299+00:00","generated_at":"2026-06-18T19:01:29.007202+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tyra Biosciences expands TYRA-300 into achondroplasia with positive preclinical data; TYRA-200 IND cleared","bullets":["TYRA-300 increased body length by 17.6% in FGFR3 Y367C/+ mice (p<0.0001); femur +24.4%, tibia +38.3%, L4-L6 +23.9%.","Company plans to submit IND for Phase 2 study in pediatric achondroplasia in 2024.","FDA cleared IND for TYRA-200, an FGFR1/2/3 inhibitor; first patient dosing expected H2 2023.","Compensation Committee adopted annual incentive plan; CEO target bonus 50% of base salary, other execs 40%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-055156","json":"https://secwatch.observer/filing/0001193125-23-055156.json","markdown":"https://secwatch.observer/filing/0001193125-23-055156.md","text":"https://secwatch.observer/filing/0001193125-23-055156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312523055156/0001193125-23-055156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312523055156/d446194d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T19:01:29.007202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}